Mirabegron in Patients With Age-Related Macular Degeneration
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-80
SponsorUniversity of Naples
About this trial
The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.
The main question it aims to answer is:
• Is there any change in outer retina morphology in patients treated?
Researchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.
Participants will:
* Take Mirabegron or Solifenacin every day for 12 months * Visit the clinic once every 6 months for checkups and tests
Eligibility criteria
Qualifiers
Age subjects 50 and 80 years-old
Ability to express informed consent
Early or moderate dry AMD according to ARDS classification
Overreactive bladder
Disqualifiers
• Any medical condition which contraindicates the use of beta-agonists
Uncontrolled hypertension
Tachycardia or atrial fibrillation
Any allergies to the beta-agonists
Trial design
Treatments tested in this trial
- Mirabegron 50mg
- Solifenacin 5mg
Treatment groups
312 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Naples
Lead sponsor
Medical University of Lublin
Collaborator
Source ClinicalTrials.gov